Drug intelligence / Profile preview

Refnot + cisplatin + gemcitabine

Development stage: Unknown
Lead developer: Eli Lilly
Modality: Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
Administration: Intravenous, Subcutaneous

Overview

This combination involves **Refnot**, a domestic immunomodulator that combines recombinant tumor necrosis factor-alpha and thymosin-α1, used to enhance antitumor and immunomodulating effects[5]. **Cisplatin** is a platinum-based chemotherapy drug that works by cross-linking DNA, which interferes with cell division by damaging DNA in several different ways to prevent cancer cells from reproducing[7]. **Gemcitabine** is a nucleoside analog used in chemotherapy, which works by inhibiting DNA synthesis, leading to cell death in rapidly dividing cells like cancer cells[6][8].

Targets

DNATNFRSF1A (Tumor necrosis factor receptor superfamily member 1A)RNR (Ribonucleotide reductase)

Beyond the preview

Go deeper on Refnot + cisplatin + gemcitabine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Refnot + cisplatin + gemcitabine.

Explore the full profile